.
MergerLinks Header Logo

Announced

Completed

Novo, Catalio Capital Management and SymBiosis led a $100m Series B extension round in Metagenomi.

Financials

Edit Data
Transaction Value£82m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Cross Border

Private Equity

Single Bidder

Minority

Biotechnology

genetic medicines

United States

Venture Capital

Completed

Acquisition

Private

Friendly

Synopsis

Edit

Novo, Catalio Capital Management and SymBiosis led a $100m Series B extension round in Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems. "At Novo Holdings, our purpose is to improve people’s health and the sustainability of society and the planet. Metagenomi continues to display an impressive track record of rapidly developing novel gene editing systems and advancing them through preclinical validation," Ray Camahort, Novo Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US